Equities Analysts Issue Forecasts for BHST Q1 Earnings

BioHarvest Sciences Inc. (NASDAQ:BHST) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for BioHarvest Sciences in a research report issued to clients and investors on Tuesday, April 14th. HC Wainwright analyst A. Dayal forecasts that the company will post earnings of ($0.04) per share for the quarter. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.07 EPS and FY2028 earnings at $0.37 EPS.

Other research analysts also recently issued research reports about the stock. Roth Mkm started coverage on shares of BioHarvest Sciences in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $12.50.

BioHarvest Sciences Stock Up 0.7%

Shares of BioHarvest Sciences stock opened at $4.30 on Thursday. The company has a market cap of $84.35 million, a price-to-earnings ratio of -7.05 and a beta of 1.16. The company’s 50 day moving average is $4.44 and its 200 day moving average is $6.24. BioHarvest Sciences has a twelve month low of $4.10 and a twelve month high of $12.80. The company has a quick ratio of 3.38, a current ratio of 3.97 and a debt-to-equity ratio of 0.10.

Hedge Funds Weigh In On BioHarvest Sciences

Several institutional investors have recently made changes to their positions in BHST. Virtu Financial LLC bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $60,000. Geode Capital Management LLC bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $61,000. HRT Financial LP bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $75,000. Marshall Wace LLP bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $110,000. Finally, Quadrature Capital Ltd bought a new position in shares of BioHarvest Sciences in the 4th quarter worth approximately $140,000.

Key Headlines Impacting BioHarvest Sciences

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: HC Wainwright now models a FY2026 loss of ($0.22) and quarter-by-quarter 2026 EPS of ($0.04), ($0.09), ($0.05) and ($0.04). Those FY2026 figures imply a much smaller loss than the consensus (-$0.80), which reduces near-term financing and path‑to‑profit concerns. MarketBeat Report
• Neutral Sentiment: The note gives detailed quarter-level guidance for 2026 and projects positive earnings in later years (FY2027 and beyond in HC Wainwright’s model), providing clearer visibility on the firm’s expected cadence to profitability — useful but not a guaranteed outcome. MarketBeat Report
• Negative Sentiment: HC Wainwright cut long‑term estimates: FY2027 from $0.22 to $0.07, FY2028 from $0.55 to $0.37 and FY2029 from $1.00 to $0.80. Those downgrades reduce the company’s growth trajectory and likely lower valuation assumptions, which is the main negative driver for today’s pullback. MarketBeat Report

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.